IKT News and Press, Inhibikase Therapeutics Inc. From 11/14/22

Inhibikase Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity PR Newswire Company to host conference call and webcast on November 15, 2022 at 8:00am ET BOSTON and ATLANTA , Nov. 14, 2022 /PR...

Inhibikase Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022 PR Newswire BOSTON and ATLANTA , Nov. 8, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmac...

Inhibikase Therapeutics ( NASDAQ: IKT ) stock fell ~ 36% on Monday after the company said that the U.S. Food and Drug Administration (FDA) issued a clinical hold on its IkT-148009 201 program in Parkinson's disease and the use of IkT-148009 in Multiple System...

Inhibikase Therapeutics Announces FDA Clinical Hold on IkT-148009 Programs PR Newswire BOSTON and ATLANTA , Nov. 7, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company d...

Inhibikase Therapeutics to Present at the Cambridge Healthtech Institute's Inaugural Neurodegeneration Targets Conference PR Newswire BOSTON and ATLANTA , Oct. 12, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinic...

Inhibikase Therapeutics to Present at the Grand Challenges in Parkinson's Disease Conference PR Newswire BOSTON and ATLANTA , Sept. 21, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical comp...

Inhibikase Therapeutics to Present Data from Phase 1/1b study of IkT-148009 at the Movement Disorders Society Congress PR Newswire IkT-148009 was well-tolerated with high systemic exposure and persistent penetration into the central nervous system (CNS) in older and el...

Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders PR Newswire BOSTON and ATLANTA , Sept. 8, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage ph...

Inhibikase Therapeutics Appoints Gisele Dion to Board of Directors PR Newswire BOSTON and ATLANTA , Sept. 1, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therape...

Penny stocks are shares of companies trading for less than $5, by definition. But what should you know about stocks priced even lower? Volatility and speculation tend to play leading roles, especially when there are active catalysts to consider. It might be rumors about a potential buyout o...